Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Back

ESC Premium Access

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Session: Non-statin Treatment of Dyslipidemia

Topic: Scores

Speaker: Ms J. Pavlovic (Rotterdam, NL)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Ms Jelena Pavlovic

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

0 follower

7 more presentations in this session

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

Speaker: Professor K. Ray (London, GB)

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.

Speaker: Doctor L. Lobo (Buenos Aires, AR)

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups

Speaker: Professor D. Bhatt (New York, US)

REDUCE-IT: accumulation of data across prespecified interim analyses to final results

Speaker: Professor B. Olshansky (Iowa City, US)

Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.

Speaker: Professor J. Ferrieres (Toulouse, FR)

Access the full session

Non-statin Treatment of Dyslipidemia

Speakers: Ms J. Pavlovic, Professor K. Ray, Doctor L. Lobo, Professor D. Bhatt, Professor B. Olshansky...

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

About the speaker

Ms Jelena Pavlovic

7 more presentations in this session

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups

REDUCE-IT: accumulation of data across prespecified interim analyses to final results

Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.

Access the full session

Non-statin Treatment of Dyslipidemia

About the event

ESC Congress 2020

ESC 365 is supported by